Satori Pharmaceuticals, a US-based developer of therapeutics for Alzheimer’s Disease, secured $15m in funding on Thursday from venture capital firms New Enterprise Associates, Prospect Venture Partners and Interwest Partners.

The round represents the culmination of the round, the first tranche of which was secured in January last year, bringing Satori’s overall funding to $40m. Early stage VC investor PureTech Ventures is also among Satori’s prior backers.

In addition to the funding, Donald Hayden, an advisor to Prospect Ventures, was elected…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?